一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

ChemicalBook >> journal list >> Advanced Science >>article
Advanced Science

Advanced Science

IF: 14.3
Download PDF

Investigating and Resolving Cardiotoxicity Induced by COVID-19 Treatments using Human Pluripotent Stem Cell-Derived Cardiomyocytes and Engineered Heart Tissues

Published:2 September 2022 DOI: 10.1002/advs.202203388 PMID: 36055796
He Xu, Ge Liu, Jixing Gong, Ying Zhang, Shanshan Gu, Zhongjun Wan, Pengcheng Yang, Yage Nie, Yinghan Wang, Zhan-peng Huang, Guanzheng Luo, Zhongyan Chen, Donghui Zhang, Nan Cao

Abstract

Coronavirus disease 2019 continues to spread worldwide. Given the urgent need for effective treatments, many clinical trials are ongoing through repurposing approved drugs. However, clinical data regarding the cardiotoxicity of these drugs are limited. Human pluripotent stem cell-derived cardiomyocytes (hCMs) represent a powerful tool for assessing drug-induced cardiotoxicity. Here, by using hCMs, it is demonstrated that four antiviral drugs, namely, apilimod, remdesivir, ritonavir, and lopinavir, exhibit cardiotoxicity in terms of inducing cell death, sarcomere disarray, and dysregulation of calcium handling and contraction, at clinically relevant concentrations. Human engineered heart tissue (hEHT) model is used to further evaluate the cardiotoxic effects of these drugs and it is found that they weaken hEHT contractile function. RNA-seq analysis reveals that the expression of genes that regulate cardiomyocyte function, such as sarcomere organization (TNNT2, MYH6) and ion homeostasis (ATP2A2, HCN4), is significantly altered after drug treatments. Using high-throughput screening of approved drugs, it is found that ceftiofur hydrochloride, astaxanthin, and quetiapine fumarate can ameliorate the cardiotoxicity of remdesivir, with astaxanthin being the most prominent one. These results warrant caution and careful monitoring when prescribing these therapies in patients and provide drug candidates to limit remdesivir-induced cardiotoxicity.

Substances (1)

Related products
Procduct Name CAS Molecular Formula Supplier Price
APILIMOD 541550-19-0 C23H26N6O2 135 suppliers Inquiry

Similar articles

IF:4.2

Dexamethasone: Therapeutic potential, risks, and future projection during COVID-19 pandemic

European journal of pharmacology Sobia Noreen, Irsah Maqbool,etc Published: 5 March 2021
IF:0.8

Establishment of a CPAMD8-GFP reporter human embryonic stem cell line, IBBDe001-B, using CRISPR/Cas9 editing

Stem cell research Shun Zhang, Jiahang Li,etc Published: 22 November 2024
IF:7.6

Efficacy and safety of SIM0417 (SSD8432) plus ritonavir for COVID-19 treatment: a randomised, double-blind, placebo-controlled, phase 1b trial

The Lancet Regional Health: Western Pacific Fuxiang Wang , Wen Xiao ,etc Published: 1 September 2023
淮安市| 榕江县| 昭苏县| 临武县| 五指山市| 洛宁县| 赤城县| 密云县| 汝南县| 宝鸡市| 泾源县| 龙泉市| 浦北县| 萨嘎县| 福建省| 尉氏县| 怀化市| 湖南省| 新邵县| 耒阳市| 姜堰市| 阿城市| 辽阳县| 休宁县| 古交市| 乐业县| 泸溪县| 寻乌县| 玉树县| 衡山县| 广平县| 孟津县| 定边县| 无锡市| 台湾省| 大石桥市| 保定市| 九龙城区| 黄梅县| 西和县| 铜陵市|